Intelligence / Healthtech / New Clinical Trials / Novo Nordisk A/S
Novo Nordisk A/S
28 Oct 2026: Trial registered · A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 28 Oct 2026
- Title
- A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China
- Conditions
- Cardiovascular Risk, Chronic Kidney Disease
- Phase
- Phase 4
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- China
- Country
- China
- Reference
- NCT07900438
- Location
- China
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Novo Nordisk A/S
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Novo Nordisk A/S in our registers.
More from China
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.